Cargando…
Direct-acting Anticoagulants in Chronic Coronary Syndromes
Direct-acting oral anticoagulants (DOACs) are easier to use, safer than and as effective as vitamin K antagonists (VKA) in the treatment of non-valvular AF (NVAF). Because of their favourable safety profile and easier use than VKAs, DOACs as anti-thrombotic therapy may have a role in the management...
Autores principales: | Sorbets, Emmanuel, Steg, Philippe Gabriel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066807/ https://www.ncbi.nlm.nih.gov/pubmed/32180831 http://dx.doi.org/10.15420/ecr.2018.24.2 |
Ejemplares similares
-
Interhospital and interindividual variability in secondary prevention: a comparison of outpatients with a history of chronic coronary syndrome versus outpatients with a history of acute coronary syndrome (the iASPIRE Study)
por: Curneen, James MG, et al.
Publicado: (2021) -
Convalescent troponin and cardiovascular death following acute coronary syndrome
por: Adamson, Philip D, et al.
Publicado: (2019) -
Clinical and budget impacts of changes in oral anticoagulation prescribing for atrial fibrillation
por: Orlowski, Andi, et al.
Publicado: (2021) -
Nocturnal respiratory rate as a predictor of mortality in patients with acute coronary syndrome
por: Eick, Christian, et al.
Publicado: (2018) -
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
por: Dagenais, Gilles R, et al.
Publicado: (2021)